Monopar Therapeutics (MNPR) Stock Price, News & Analysis

Company Overview

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Key Stats

• Today's Range: $35.65 to $40.33
• 50-Day Range: $28.89 to $44.96
• 52-Week Range: $1.72 to $54.30
• Volume: 14,846 shs
• Average Volume: 360,773 shs
• Market Capitalization: $227.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $55.33
• Consensus Rating: Moderate Buy

Monopar Therapeutics Stock Analysis - MarketRank™

Monopar Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 811th out of 1,850 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Monopar Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Monopar Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Monopar Therapeutics are expected to decrease in the coming year, from ($1.65) to ($2.51) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Monopar Therapeutics is -18.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Monopar Therapeutics is -18.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Monopar Therapeutics has a P/B Ratio of 19.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.11% of the float of Monopar Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Monopar Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Monopar Therapeutics has recently decreased by 5.77%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Monopar Therapeutics does not currently pay a dividend.

Dividend Growth

Monopar Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.11% of the float of Monopar Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Monopar Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Monopar Therapeutics has recently decreased by 5.77%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.11

News Sentiment

Monopar Therapeutics has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Monopar Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for MNPR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Monopar Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Monopar Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,166,690.00 in company stock.

Percentage Held by Insiders

20.50% of the stock of Monopar Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 1.83% of the stock of Monopar Therapeutics is held by institutions.

MNPR Stock Analysis - Frequently Asked Questions

How have MNPR shares performed this year?

Monopar Therapeutics' stock was trading at $22.00 on January 1st, 2025. Since then, MNPR shares have increased by 68.9% and is now trading at $37.16.
View the best growth stocks for 2025 here.

How were Monopar Therapeutics' earnings last quarter?

Monopar Therapeutics Inc. (NASDAQ:MNPR) issued its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.38) EPS for the quarter, beating analysts' consensus estimates of ($0.65) by $0.27.

When did Monopar Therapeutics' stock split?

Monopar Therapeutics shares reverse split on the morning of Tuesday, August 13th 2024. The 1-5 reverse split was announced on Friday, August 9th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Does Monopar Therapeutics have any subsidiaries?

The following companies are subsidiaries of Monopar Therapeutics: Monopar Therapeutics Pty Ltd, and Monopar Therapeutics SARL.

When did Monopar Therapeutics IPO?

Monopar Therapeutics (MNPR) raised $9 million in an IPO on Thursday, December 19th 2019. The company issued 1,100,000 shares at $8.00 per share. JonesTrading served as the underwriter for the IPO and Arcadia Securities was co-manager.

Who are Monopar Therapeutics' major shareholders?

Top institutional investors of Monopar Therapeutics include ADAR1 Capital Management LLC (1.65%), Affinity Asset Advisors LLC (1.01%), Goldman Sachs Group Inc. (0.30%) and OMERS ADMINISTRATION Corp (0.15%). Insiders that own company stock include Tactic Pharma Llc, Andrew Cittadine and Karthik Radhakrishnan.
View institutional ownership trends.

How do I buy shares of Monopar Therapeutics?

Shares of MNPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Monopar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Monopar Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), GlycoMimetics (GLYC), Tonix Pharmaceuticals (TNXP).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 5/17/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MNPR
• CIK: 1645469
• Web: www.monopartx.com
• Phone: 847-388-0349
• Fax: N/A
• Employees: 10
• Year Founded: 2014

Price Target and Rating

• Average Stock Price Target: $55.33
• High Stock Price Target: $76.00
• Low Stock Price Target: $40.00
• Potential Upside/Downside: +48.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.60)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-8,400,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -107.21%
• Return on Assets: -87.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.41
• Quick Ratio: 5.41

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.88 per share
• Price / Book: 19.77

Miscellaneous

• Outstanding Shares: 6,115,000
• Free Float: 3,972,000
• Market Cap: $227.23 million
• Optionable: Not Optionable
• Beta: 1.11